![](https://endpts.com/wp-content/uploads/2021/03/David-Liu-tile-Broad-Institute-scaled.jpg)
David Liu (courtesy Broad Institute)
They’re going for it: David Liu’s preclinical biotech shoots for a (maybe $200M) IPO
Can a preclinical biotech with grand ambitions, a star scientific founder and enthusiastic backers with deep pockets fly a big IPO against the gale force …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.